TABLE 1.
Overview of importance and MCIDs of outcomes used in the update of the T2DM guideline 2
| Outcomes | Importance a | Cut‐off point for clinical relevance | MCID based on |
|---|---|---|---|
| All‐cause mortality | critical | RRR 10% (RR <0,9 or RR >1,1) | Expert opinion guideline committee |
| Macrovascular morbidity | critical | RRR 25% (RR <0,75 of RR >1,25) | GRADE 13 |
| Microvascular morbidity | critical | RRR 25% (RR <0,75 or RR >1,25) | GRADE 13 |
| Quality of life | critical | every statistically significant difference or SMD = 0,5 | GRADE 13 |
| Severe hypoglycemia | critical | RRR 25% (RR <0,75 of RR >1,25) | GRADE 13 |
| Other adverse events | critical or important b | every statistically significant difference or SMD = 0,5 | GRADE 13 |
| Hospital admissions | important | RRR 25% (RR <0,75 of RR >1,25) | GRADE 13 |
| Change in HbA1c | important | 0,5% or 5 mmol/mol | NICE guideline Type 2 diabetes in adults: management 11 |
| Change in body weight | important |
5% in case of both treatments cause weight gain 2,5% in case of one treatment causes weight loss and the other causes weight gain (or had a neutral effect on weight) |
Dutch guideline T2DM in secondary care 12 |
| Other hypoglycemia (not specified or mild or modest) | important | RRR 25% (RR <0,75 of RR >1,25) | GRADE 13 |
Abbreviations: RRR, relative risk reduction; RR, relative risk; SMD, standardized mean difference.
a
Minor differences existed in relative importance between different healthcare questions. The importance shown is based on the importance for most healthcare questions.
b
Depending on the severity of the adverse event.